Li Yu - 15 Mar 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
VP Cntrllr/Prncpl Acctng Offcr
Signature
/s/ Li Yu
Issuer symbol
OCX
Transactions as of
15 Mar 2022
Transactions value $
$0
Form type
4
Filing time
17 Mar 2022, 21:29:52 UTC
Previous filing
14 Oct 2021
Next filing
19 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +37.5K $0.00 37.5K 15 Mar 2022 Common Stock 37.5K $1.15 Direct F1
transaction OCX Option to Purchase Common Stock Award $0 +37.5K $0.00 37.5K 15 Mar 2022 Common Stock 37.5K $1.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
F2 Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.